Additionally, the highly potent toxin used in SHR-A1811 allows for a lower DAR of 6, potentially reducing circulating toxin levels.29 Unlike most other HER2-directed ADCs in clinical development for NSCLC, which utilize microtubule inhibitors as payloads,33 SHR-A1811 employs a topoisomerase I inhibitor. Here, ERBB2 is linked to non-small cell lung carcinoma.